Prevalence of neuronal cell surface antibodies in patients with psychotic illness - extension study. Determining the clinical relevance of pathogenic antibodies in psychosis.


Study ID: 18451
Short Title: PPiP2
Organisation: Southern Health NHS Foundation Trust
Location: Moorgreen Hospital
Condition: Psychosis
Main Specialty: Mental Health
Expected End Date: 30/08/2020
Postcode: SO30 3JB
Contact Name: SHFT Research
Contact Email: research@southernhealth.nhs.uk
Active: Yes

Inclusion Criteria

1. Male or Female, aged 14-35. Diagnosis of first episode psychotic illness, PANSS score of 4 or more on Positive Scale items 1, 3, 5, 6 or General Scale items 9.


2. Less than 6 months of antipsychotic medication.

Exclusion Criteria

Any other neurological disorders including multiple sclerosis, epilepsy, cerebrovascular disease, hydrocephalus, traumatic brain injury, meningo-encephalitis, systemic lupus erythematosus, CNS vasculitis. Primary drug induced psychosis.

Study summary:

The PPiP study aims to understand if some cases of psychosis are caused by immune system problems in some people.
The immune system normally controls our ability to fight infection. If the immune system goes wrong it may cause diseases called ‘autoimmune’ diseases. We can diagnose some of these autoimmune diseases using blood tests. We are specifically interested in antibodies affecting the N-methyl D-aspartate receptors (NMDA-r) or other neuronal membrane targets that may be the cause symptoms of psychosis and possibly cause some cases of schizophrenia. We are working with Early Intervention in Psychosis (EIP) services across England to estimate the prevalence of these autoimmune diseases in people with first episode psychosis.


« Study Map« List of studies